CA Patent

CA2782179A1 — Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin

Assigned to Boehringer Ingelheim International GmbH · Expires 2011-06-03 · 15y expired

What this patent protects

The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.

USPTO Abstract

The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.

Drugs covered by this patent

Jardiance (empagliflozin) · Boehringer Ingelheim

Patent Metadata

Patent number: CA2782179A1
Jurisdiction: CA
Classification: —
Expires: 2011-06-03
Drug substance claim: No
Drug product claim: No
Assignee: Boehringer Ingelheim International GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.